NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The global hypoparathyroidism market size is estimated to grow by USD 474.9 million from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 7.6% during the forecast period. Increased awareness programs for thyroid treatment is driving market growth, with a trend towards growing use of inorganic growth strategies by vendors.
However, implementation of stringent regulations poses a challenge.Key market players include AdvaCare Pharma, Alkem Laboratories Ltd., Ascendis Pharma AS, AstraZeneca Plc, Cipla Inc.
, COSCIENS BIOPHARMA, Extend Biosciences Inc, F. Hoffmann La Roche Ltd., La Renon Healthcare Pvt.
Ltd., LLOYD Inc., Lupin Ltd.
, Merck and Co. Inc., Pfizer Inc.
, Sigmapharm Laboratories LLC, Sun Pharmaceutical Industries Ltd., VISEN Pharmaceuticals Co Ltd, and Wockhardt Ltd..
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report Market Driver The global hypoparathyroidism market is experiencing a significant trend towards inorganic growth strategies, as companies look to expand their capabilities and market presence. AstraZeneca's acquisition of Amolyt Pharma in March 2024 is a prime example of this trend.
This strategic move adds the promising investigational therapeutic peptide , eneboparatide (AZP-3601), to AstraZeneca's portfolio. Eneboparatide's novel mechanism of a.